financetom
Business
financetom
/
Business
/
Cal-Maine Foods Stock Cracks After Egg Producer Reports Q3 Results, Inks Deal To Acquire Echo Lake Foods
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cal-Maine Foods Stock Cracks After Egg Producer Reports Q3 Results, Inks Deal To Acquire Echo Lake Foods
Apr 8, 2025 2:16 PM

Cal-Maine Foods Inc ( CALM ) shares are trading lower in Tuesday’s after-hours session after the company reported third-quarter financial results and announced plans to acquire Echo Lake Foods.

Q3 Earnings: Cal-Maine reported fiscal third-quarter revenue of $1.42 billion, missing analyst estimates of $1.43 billion, according to Benzinga Pro. The egg producer reported third-quarter earnings of $10.38 per share, beating analyst estimates of $7.93 per share.

Cal-Maine reported a 14% year-over-year increase in the average number of layer hens during the quarter. The company also reported a 33% increase in breeder flocks and a 24% increase in total chicks hatched during the quarter.

Cal-Maine’s board approved a $500 million share repurchase program during the third quarter and declared a cash dividend of approximately $3.46 per share.

Don’t Miss: Trump Claims Egg Prices Are ‘WAY DOWN’ As US Plans Imports From Turkey and South Korea

“Dynamic market conditions and HPAI-related supply shortages persisted this quarter. However, the entire Cal-Maine Foods ( CALM ) team did an outstanding job in maximizing production through a period of high demand, while operating safely and maintaining diligence on biosecurity measures,” said Sherman Miller, president and CEO of Cal-Maine Foods ( CALM ).

“We were fortunate to have the ability to utilize our existing operational scale and to benefit from recent acquisitions, which helped increase our production capacity in this challenging supply environment.”

In addition to earnings, Cal-Maine announced that it signed a definitive agreement to acquire Echo Lake Foods for approximately $258 million. Echo Lake Foods produces ready-to-eat egg products and breakfast foods.

The transaction has been approved by both companies’ boards and is expected to close by the end of fiscal 2025.

CALM Price Action: Cal-Maine shares were down 4.57% after-hours, trading at $86.20 at the time of publication Tuesday, according to Benzinga Pro.

Read Next:

• Trump Unleashes ‘Beautiful Clean Coal’ Policies As Wall Street Tanks, S&P 500 Hits 1-Year Low

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
May 24, 2024
08:25 AM EDT, 05/24/2024 (MT Newswires) -- Verastem Oncology (VSTM) late Thursday reported that an ongoing phase 1/2 clinical trial evaluating avutometinib and defactinib in combination with gemcitabine and nab-paclitaxel in 41 patients with metastatic pancreatic cancer reached an interim partial response rate of 83%. Of 26 patients in all the trial cohorts who have had their first scan while...
--Cato Keeps Quarterly Dividend at $0.17 per share, Payable June 24 to Shareholders of Record June 10
--Cato Keeps Quarterly Dividend at $0.17 per share, Payable June 24 to Shareholders of Record June 10
May 24, 2024
08:17 AM EDT, 05/24/2024 (MT Newswires) -- Price: 5.73, Change: -0.05, Percent Change: -0.87 ...
E3 Lithium Narrows Q1 Loss; Company Hasn't Started Commercial Production or Generated Cash Flow
E3 Lithium Narrows Q1 Loss; Company Hasn't Started Commercial Production or Generated Cash Flow
May 24, 2024
08:25 AM EDT, 05/24/2024 (MT Newswires) -- E3 Lithium ( EEMMF ) on Friday reported a narrower loss for the first quarter even though the company has not generated revenues from operations and had an accumulated deficit of $45.2 million at the end of March. The company reported a first-quarter net loss of $2.4 million, or $0.03 per share, compared...
Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation
Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation
May 24, 2024
08:17 AM EDT, 05/24/2024 (MT Newswires) -- Organon (OGN) and Shanghai Henlius Biotech said Friday their marketing authorization applications for HLX14, a denosumab biosimilar, have been validated by the European Medicines Agency. The submissions were based on a phase 3 study comparing HLX14 with denosumab in postmenopausal women with osteoporosis, the companies said. Henlius licensed HLX14 to Organon in 2022...
Copyright 2023-2025 - www.financetom.com All Rights Reserved